719 related articles for article (PubMed ID: 29266249)
61. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
[TBL] [Abstract][Full Text] [Related]
62. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
63. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
64. Complement and myasthenia gravis.
Sanderson NSR
Mol Immunol; 2022 Nov; 151():11-18. PubMed ID: 36063582
[TBL] [Abstract][Full Text] [Related]
65. Myasthenia gravis as a prototype autoimmune receptor disease.
Hoedemaekers AC; van Breda Vriesman PJ; De Baets MH
Immunol Res; 1997; 16(4):341-54. PubMed ID: 9439759
[TBL] [Abstract][Full Text] [Related]
66. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
Mori S; Shigemoto K
Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
[TBL] [Abstract][Full Text] [Related]
67. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.
Morgan BP; Chamberlain-Banoub J; Neal JW; Song W; Mizuno M; Harris CL
Clin Exp Immunol; 2006 Nov; 146(2):294-302. PubMed ID: 17034582
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
Biesecker G; Gomez CM
J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
[TBL] [Abstract][Full Text] [Related]
69. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
70. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.
Huda R; Strait RT; Tüzün E; Finkelman FD; Christadoss P
J Neuroimmunol; 2015 Apr; 281():68-72. PubMed ID: 25867470
[TBL] [Abstract][Full Text] [Related]
71. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients.
Lekova E; Zelek WM; Gower D; Spitzfaden C; Osuch IH; John-Morris E; Stach L; Gormley D; Sanderson A; Bridges A; Wear ER; Petit-Frere S; Burden MN; Priest R; Wattam T; Kitchen SJ; Feeney M; Davis S; Morgan BP; Nichols EM
Front Immunol; 2022; 13():968206. PubMed ID: 36148231
[TBL] [Abstract][Full Text] [Related]
72. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
73. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
74. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
75. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
[TBL] [Abstract][Full Text] [Related]
76. [Pathogenic antibodies in myasthenia gravis].
Motomura M
Brain Nerve; 2010 Apr; 62(4):411-8. PubMed ID: 20420182
[TBL] [Abstract][Full Text] [Related]
77. Complement Inhibition for the Treatment of Myasthenia Gravis.
Mantegazza R; Vanoli F; Frangiamore R; Cavalcante P
Immunotargets Ther; 2020; 9():317-331. PubMed ID: 33365280
[TBL] [Abstract][Full Text] [Related]
78. Factors in the production of experimental autoimmune myasthenia gravis in acetylcholine receptor immunized rabbits.
Niemi WD; Nastuk WL; Chang HW; Plescia OJ; Plescia AM
Ann N Y Acad Sci; 1981; 377():222-36. PubMed ID: 6951475
[TBL] [Abstract][Full Text] [Related]
79. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
[TBL] [Abstract][Full Text] [Related]
80. The immunopathology of myasthenia gravis.
Lennon VA
Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
